Human Malignant Glioma Cell Lines are Refractory to Retinoic Acid-Mediated Differentiation and Sensitization to Apoptosis 1

Cellular Physiology and Biochemistry

Volumn 10, Issue 3, 2000, Pages 159-168

  Schmidt, Friederike ^a   Groscurth, Peter ^a,b   Dichgans, Johannes ^a,b   Weller, Michael ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Brain; Glioma; Neuroblastoma; Retinoids

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID;

ANIMAL; APOPTOSIS; ARTICLE; ASTROCYTE; CELL DIFFERENTIATION; DRUG EFFECT; DRUG INTERACTION; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; RAT; STEREOISOMERISM;

ANIMALS; APOPTOSIS; ASTROCYTES; CELL DIFFERENTIATION; DRUG INTERACTIONS; GLIOMA; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; STEREOISOMERISM; TRETINOIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033655188     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000016346     Document Type: Article

References (30)

1. Lu XP, Fanjul A, Picard N, Pfahl M, Rungta D, Nared-Hood K, Carter B, Piedrafita J, Tang S, Fabbrizio E, Pfahl M: Novel retinoid-rclated molécules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nature Med 1997;3:686-690.
2. Nagy L, Thomazy VA, Heyman R, Davies PA: Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 1998;5:11-19.
3. Rutka JT, De Armond SJ, Giblin J, McCulloch JR, Wilson CB, Rosenblum ML: Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 1998;42:419-427.
4. YungWKA,LotanR, Lee P.LotanD, Steck PA: Modulation of growth and epidermal growth factor receptor activity by retinoic acid in human glioma cells. Cancer Res 1989;49:1014-1019.
5. YungWK, KyritsisAP.GleasonMJ, Levin VA: Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996;2:1931-1935.
6. Defer GL, Adle-Biassette H, Ricolfi F, Martin L, Authier FJ, Chomienne C, Degos L, Degos JD: All-trans-retinoic acid in relapsing malignant gliomas: clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J Neuro-Oncol 1997;34:169-177.
7. Kaba SE, Kyritsis AP, Conrad C, Gleason MJ, Newman R, Levin VA, Yung WKA: The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin). J NeuroOncol 1997:34:145-151.
8. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WKA: All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J NeuroOncol 1997;34:193-200.
9. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A: Loco-regional Fas/ APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-2258.
10. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, Von Deimling A, Dichgans J: Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 1998;79:640-644.
11. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M: Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J Neuro-Oncol 1998;39:19-32.
12. Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC: Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. Neurol Res 1997;19:459-470.
13. Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M: Death ligand/ receptor-independent caspase activation mediates drug-induced cell death in malignant glioma cells. Oncogene 1999;18:5044-5053.
14. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M: Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. Br J Cancer 1998;77:404411.
15. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A: Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-964.
16. Weller M, Kleihues P, Dichgans J, Ohgaki H: CD95 ligand: lethal weapon for malignant glioma? Brain Pathol 1998;8:285-293.
17. Okamura T, Masuda M, Arai Y, Ishida C, Shudou K, Mizoguchi H: All-trans-retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1. Exp Hematol 1998;26:501-506.
18. Bissonnette RP, Brunner T, Lazarchik SB, Yoo NJ, Boehm MF, Green DR, Heyman RA: 9-cis-retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of Fas ligand and requires retinoic acid receptor and retinoic X receptor activation. Mol Cell Biol 1995;15:55765585.
19. Noguchi K, Nakajima M, Naito M, Tsuruo T: Inhibition by differentiation-inducing agents of wild-type p53-dependent apoptosis in HL60 cells. Jpn J Cancer Res 1995;86:217-223.
20. Naumann U, Durka S, Weller M: Dexamethasone-mediated protection from drug toxicity linked to p21WAF'clpl protein accumulation. Oncogene 1998;17:15671575.
21. Fanjul AN, Bouterfa H, Dawson M, Pfahl M: Potential role for retinoic acid receptor-γ in the inhibition of breast cancer cells by selective retinoids and interferons. Cancer Res 1996:56:1571-1577.
22. Weihua X, Kolla V, Kalvakolanu DV: Modulation of interferon action by retinoids. J Biol Chem 1997;272:9742-9748.
23. Agarwal N, Mehta K: Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells. Biochem Biophys Res Commun 1997;230:251-253.
24. HuZB, Minden MD, McCulloch EA: Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia 1995;9:1667-1673.
25. Tosi P, Pellacani A, Visani G, Ottaviani E, Ronconi S, Zamagni E, Benni M, Cavo M, Tura S: In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur J Haematol 1999;62:143-148.
26. Lasorella A, lavarone A, Israel MA: Differentiation of neuroblastoma enhances bcl-2 expression and induces alterations of apoptosis and drag resistance. Cancer Res 1995;55:4711-4716.
27. Kleinschmidt-DeMasters BK, Orr EA, Savelieva E, Owens GC, Kruse CA: Paucity of retinoid acid receptor alpha (RARa) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression. J Neuro-Oncol 1999;41:31-42.
28. PuduvalliVK,SaitoY,XuR,Kouraklis GP, Levin VA, Kyritsis AP: Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 1999;5:2230-2235.
29. Bouterfa H, Picht T, Kess D, Herbold C, Noll E, Black PM, Roosen K, Tonn JC: Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in etablished cell lines. Neurosurgery 2000;46:419-430.
30. Dirks PB, Patel K, Hubbard SL, Ackerley C, Hamel PA, Rutka JT: Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. Oncogens 1997;15:2037-2048.